| Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRA S and Presence of PIK3CA/AKT1 Mutations N Rekhtman, PK Paik, ME Arcila, LJ Tafe, GR Oxnard, AL Moreira, ... Clinical cancer research 18 (4), 1167-1176, 2012 | 446 | 2012 |
| Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis YY Janjigian, D Werner, C Pauligk, K Steinmetz, DP Kelsen, E Jäger, ... Annals of oncology 23 (10), 2656-2662, 2012 | 383 | 2012 |
| Pathologist-level classification of histologic patterns on resected lung adenocarcinoma slides with deep neural networks JW Wei, LJ Tafe, YA Linnik, LJ Vaickus, N Tomita, S Hassanpour Scientific reports 9 (1), 3358, 2019 | 295 | 2019 |
| Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms LJ Tafe, K Garg, I Chew, C Tornos, RA Soslow Modern Pathology 23 (6), 781-789, 2010 | 250 | 2010 |
| Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden C Morrison, S Pabla, JM Conroy, MK Nesline, ST Glenn, D Dressman, ... Journal for immunotherapy of cancer 6, 1-12, 2018 | 136 | 2018 |
| Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion D Chakravarty, A Johnson, J Sklar, NI Lindeman, K Moore, S Ganesan, ... Journal of Clinical Oncology 40 (11), 1231-1258, 2022 | 135 | 2022 |
| The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma A Biernacka, PD Tsongalis, JD Peterson, FB de Abreu, CC Black, ... Cancer genetics 209 (5), 195-198, 2016 | 120 | 2016 |
| Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma N Rekhtman, LJ Tafe, JE Chaft, L Wang, ME Arcila, A Colanta, AL Moreira, ... Modern Pathology 26 (4), 511-522, 2013 | 119 | 2013 |
| Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy C von Bodman, G Godoy, DC Chade, A Cronin, LJ Tafe, SW Fine, ... The Journal of urology 184 (1), 143-148, 2010 | 99 | 2010 |
| Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors JM Conroy, S Pabla, MK Nesline, ST Glenn, A Papanicolau-Sengos, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 93 | 2019 |
| Implementation of a molecular tumor board: the impact on treatment decisions for 35 patients evaluated at Dartmouth-Hitchcock Medical Center LJ Tafe, IP Gorlov, FB De Abreu, JA Lefferts, X Liu, JR Pettus, JD Marotti, ... The oncologist 20 (9), 1011-1018, 2015 | 90 | 2015 |
| Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients S Pabla, JM Conroy, MK Nesline, ST Glenn, A Papanicolau-Sengos, ... Journal for immunotherapy of cancer 7, 1-13, 2019 | 86 | 2019 |
| Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization LJ Tafe, YY Janjigian, M Zaidinski, CV Hedvat, MR Hameed, LH Tang, ... Archives of pathology & laboratory medicine 135 (11), 1460-1465, 2011 | 86 | 2011 |
| ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma L Romero-Pérez, MÁ López-García, J Díaz-Martín, M Biscuola, ... Modern Pathology 26 (11), 1514-1524, 2013 | 83 | 2013 |
| Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome JL Dillon, JL Gonzalez, L DeMars, KJ Bloch, LJ Tafe Human pathology 70, 121-128, 2017 | 79 | 2017 |
| Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results … KE Muller, JD Marotti, VA Memoli, WA Wells, LJ Tafe American journal of clinical pathology 144 (2), 247-252, 2015 | 61 | 2015 |
| Lynch syndrome presenting as endometrial cancer LJ Tafe, ER Riggs, GJ Tsongalis Clinical Chemistry 60 (1), 111-121, 2014 | 57 | 2014 |
| Regulatory T cells are not a strong predictor of survival for patients with glioblastoma AA Thomas, JL Fisher, GJ Rahme, TH Hampton, U Baron, S Olek, ... Neuro-oncology 17 (6), 801-809, 2015 | 55 | 2015 |
| Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer SV Carlsson, LJ Tafe, DC Chade, DD Sjoberg, N Passoni, SF Shariat, ... The Journal of urology 189 (4), 1314-1319, 2013 | 55 | 2013 |
| A Comprehensive Assay for CFTR Mutational Analysis Using Next-Generation Sequencing AN Abou Tayoun, CD Tunkey, TJ Pugh, T Ross, M Shah, CC Lee, ... Clinical chemistry 59 (10), 1481-1488, 2013 | 54 | 2013 |
